Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Income (2020 - 2025)

Historic Operating Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' Operating Income rose 1825.38% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 4065.56%. This contributed to the annual value of -$61.0 million for FY2024, which is 14284.29% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Operating Income stood at -$11.0 million, which was up 1825.38% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Operating Income registered a high of $5.8 million during Q1 2023, and its lowest value of -$35.7 million during Q4 2021.
  • Its 5-year average for Operating Income is -$11.2 million, with a median of -$9.9 million in 2022.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Operating Income crashed by 46933.14% in 2021, and later soared by 15912.08% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Operating Income (Quarter) stood at -$35.7 million in 2021, then surged by 67.35% to -$11.6 million in 2022, then crashed by 38.9% to -$16.2 million in 2023, then plummeted by 107.84% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Its Operating Income was -$11.0 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$6.8 million in Q1 2025.